SRXH Latest Press Releases

-- October 30, 2026 --

SRX Global Provides Update on Balance Sheet and Share Buyback Globe Newswire 3:16 PM

-- October 26, 2026 --

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies Globe Newswire 9:05 AM

-- October 8, 2026 --

SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform Globe Newswire 8:35 AM

-- October 7, 2026 --

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies Globe Newswire 3:00 PM

-- October 6, 2026 --

SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim Globe Newswire 4:20 PM

-- September 24, 2026 --

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) Globe Newswire 12:30 PM

-- September 23, 2026 --

SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar Globe Newswire 4:05 PM

-- September 3, 2026 --

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company Globe Newswire 8:15 AM

-- August 31, 2026 --

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers Globe Newswire 7:30 AM

-- August 13, 2026 --

SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results Globe Newswire 4:05 PM

-- August 6, 2026 --

SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET Globe Newswire 8:30 AM

-- August 4, 2026 --

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) Globe Newswire 5:00 AM

-- August 3, 2026 --

SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger Globe Newswire 8:44 AM

-- July 30, 2026 --

SRX Global Acquires Shares in Jersey Mike's $1 Billion Initial Public Offering Globe Newswire 2:04 PM

-- July 16, 2026 --

SRX Global Regains Full Compliance with NYSE American Listing Standards Globe Newswire 9:00 AM

-- July 14, 2026 --

SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026 Globe Newswire 9:20 AM

-- July 10, 2026 --

SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders Globe Newswire 8:30 AM

-- July 9, 2026 --

SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding Globe Newswire 11:42 AM

-- July 8, 2026 --

SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1) Globe Newswire 1:46 PM

SRX Global Declares One-Time Cash Dividend Globe Newswire 9:00 AM

-- July 2, 2026 --

SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines Globe Newswire 10:30 AM

-- June 24, 2026 --

SRX Global Announces Share Consolidation Globe Newswire 7:45 AM

-- June 23, 2026 --

SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences Globe Newswire 8:20 AM

-- June 18, 2026 --

SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets Globe Newswire 8:30 AM

-- June 8, 2026 --

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK) Globe Newswire 12:07 PM